Lyseen

Quick links to important sections

Lyseen

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lyseen

What is Lyseen? Defining its Chemical Identity and Core Type

Property Description
Active ingredient Pridinol (Pridinol mesylate)
Form Tablet (oral), Solution (injectable)
Pharmacological class Centrally acting skeletal muscle relaxant, Anticholinergic agent
Common use Relieving heightened muscle tone and stiffness
Origin Synthetic compound (Piperidine derivative)

Lyseen is a trade name for a medicine containing the active substance Pridinol, most often utilized as the salt Pridinol mesylate. This compound is a synthetic derivative, meaning it is manufactured chemically, and it is firmly classified as a centrally acting skeletal muscle relaxant. This pharmacological designation indicates that its primary site of action is within the central nervous system to modulate muscle function. This category of agents is clinically recognized for addressing issues of involuntary muscle tightness, differentiating it from topically applied or peripheral-acting treatments.

The core identity of the product is confirmed by its global presence, with its classification confirmed by the World Health Organization's Anatomical Therapeutic Chemical (ATC) code, M03BX03. This code establishes Lyseen as a pharmaceutical designed to influence signaling within the central nervous system rather than acting directly on muscle tissues.

Pharmacological Class and General Benefit

Lyseen's specific mechanism relies on its function as an anticholinergic agent, which involves blocking the activity of acetylcholine at specific nerve receptors. The final preparation is available for systemic use via oral administration in the form of tablets, and for more rapid intervention via parenteral administration as an injectable solution. This dual-route availability is a distinguishing feature, offering flexibility based on the necessity for onset of action.

This anticholinergic action provides a clear therapeutic rationale: by interrupting the excessive motor nerve signals that cause reflex contractions, the drug is used to relieve states of heightened muscle tightness and contractures. The general benefit, therefore, is the restoration of more relaxed, normal muscle function.

Regulatory References

  1. Synthetic Chemical Substances (PubChem)
  2. Anticholinergic Agents (NIH MeSH)
  3. Contracture (MedlinePlus)

What side effects are possible with Lyseen?

Lyseen: Possible Side Effects and Safety Information

The safety profile of Lyseen (Pridinol mesylate) is primarily defined by the official classification of its adverse reactions and specific usage constraints documented in regulatory labeling.

Adverse Reaction Scope

Category Regulatory Statement
Key adverse reaction categories Side effects are generally consistent with its anticholinergic properties, affecting the central nervous system (CNS) and the autonomic nervous system.
Frequency classification Common side effects include headache, dry mouth, dizziness, nausea, abdominal pain, asthenia, arrhythmias, and hypotension. Rare effects include impaired vision, vomiting, hypersensitivity reactions, anxiety, and depression.
System-organ classes involved Officially documented effects span Nervous System Disorders (e.g., drowsiness), Gastrointestinal Disorders (e.g., dry mouth, constipation), Eye Disorders (e.g., impaired vision, accommodation difficulties), Cardiac and Vascular Disorders (e.g., arrhythmias, hypotension), and Renal and Urinary Disorders (e.g., urinary retention).
Safety-related restrictions The medicine is contraindicated for patients with Glaucoma, Prostate hypertrophy, Syndrome with urinary retention, Gastrointestinal obstructions, and Arrhythmia. It is also restricted due to the excipient, lactose, for those with specific hereditary sugar intolerances.

Population-Specific Safety Considerations

Official labeling contains explicit restrictions for specific patient groups. Lyseen is contraindicated during the first trimester of pregnancy. Its use requires caution in older adults and in patients with severe renal or hepatic impairment due to the expectation of higher blood levels and an increased risk of circulatory problems. No data are available on its use in children and adolescents.

Regulatory Safety Summary

Regulatory documents state that adverse effects are typically rare to uncommon and are documented to generally disappear after a dose reduction or discontinuation. The drug is also noted to increase the effect of other anticholinergic medicines.

The official safety information structures the understanding of risks by categorizing possible adverse effects by frequency and system-organ class, defining the boundaries of use through explicit contraindications and mandated cautions for vulnerable populations.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Lyseen (Pridinol mesylate) overdose is defined by the drug's established pharmacological class. Government prescribing information states that an overdose may present with clinical manifestations typical for anticholinergics.


Official Regulatory Statements on Overdose Management

Feature Regulatory Statement
Documented Presentation Symptoms are typical for anticholinergics.
Antidote Physostigmine salicylate is the specific reversal agent.
Urgent Help Trigger Required when symptom severity requires intervention.

Required Emergency Actions

Immediate medical attention is necessary if an overdose is suspected or occurs. The need for urgent help is dictated by the requirement for a specific, controlled intervention that cannot be performed outside of a clinical setting. Regulatory documents mandate intervention when the symptom severity is critical.

Management involves the administration of the specific agent, physostigmine salicylate. The official procedure requires that this antidote be administered slowly and intravenously under direct medical supervision. The entire overdose profile is structured around the immediate identification of the anticholinergic syndrome and the mandated need to seek emergency medical care.

Therapeutic Uses of Lyseen

What Lyseen Treats: Main Uses and Benefits

Lyseen provides therapeutic support relevant across therapeutic domains where additional symptomatic assistance is needed. It is applied in addressing symptoms related to physical discomfort, systemic imbalance, and heightened physiological activity. This product is commonly used across conditions characterized by periods of heightened symptoms or those involving episodic or fluctuating manifestations.

The medicine is applied in clinical scenarios when symptoms intensify and supportive symptom management is appropriate, providing assistance with symptoms that create noticeable physiological strain or interfere with daily functioning. One of the key patient-oriented benefits is that it provides supportive relief during phases of increased distress, and assists with maintaining functional stability when symptoms are more noticeable.

Key areas where Lyseen is applied include managing symptoms that cause functional strain, support for acute episodes, and assistance during periods of heightened discomfort.

Quick Fact: Support for Symptomatic Discomfort

Eligibility and Restrictions for Use

Who can and cannot use Lyseen?

Eligibility for Lyseen (Pridinol mesylate) is strictly determined by official regulatory documents, which define specific population groups that must not use the medicine (contraindications) and groups requiring use under caution.

Lyseen is generally indicated for adults. Its use is not established in children and adolescents, and use in the elderly requires caution.


Absolute Contraindications (Must Not Use)

Condition / Population Status
Hypersensitivity to Pridinol or excipients Contraindicated
Glaucoma, Arrhythmia Contraindicated
Prostate Hypertrophy or Urinary Retention Contraindicated
Gastrointestinal Obstructions Contraindicated
First Trimester of Pregnancy Contraindicated
Hereditary Galactose/Lactose Disorders Contraindicated

Restricted or Conditional Use

Condition / Population Status
Severe Renal/Hepatic Insufficiency Use requires caution
Hypotension (Low Blood Pressure) Use requires caution
Second/Third Trimesters of Pregnancy Conditional use (if absolutely necessary)
Breastfeeding/Lactation Should be avoided

What should I know about interactions with other medicines?

The documented interaction profile for the active ingredient in Lyseen (Pridinol) focuses on pharmacodynamic potentiation and alterations in drug exposure specific to certain patient populations.

Documented Drug–Drug Interactions

The primary documented interaction is a pharmacodynamic potentiation when Lyseen is co-administered with other anticholinergic medicinal products. This combination results in an additive anticholinergic effect, which may increase the potential occurrence of specific adverse effects. Regulatory documentation explicitly names substances such as atropine and certain medicines used for overactive bladder or asthma as interacting agents. No other formal drug–drug interactions involving metabolic enzymes (such as CYP inhibition or induction), drug transporters, or formal contraindications based on interaction are officially listed in the prescribing information reviewed.

Population-Specific Interaction Notes

In terms of exposure, regulatory documents specify that a change in the product’s disposition is anticipated in certain patient populations. For individuals with severe renal insufficiency or severe hepatic insufficiency, the medicine’s clearance is altered. This results in an expectation of higher and/or longer-lasting blood levels of the product in these specific patients. No mandatory dose-timing separation rules or interactions with food, alcohol, or herbal products are officially documented.

Mechanism of Action

How Lyseen Works

Lyseen functions as a pathway modulator, engaging mechanisms that influence dysregulated molecular processes by targeting key signaling domains. Its action initiates specific molecular modifications that elicit defined alterations in physiological systems.


Modulation of Receptor-Mediated Signaling

Lyseen acts within domains involving specific receptor-mediated signaling to modulate sequences that contribute to rapid physiological activation. It modifies early molecular steps, leading to the reduction of targeted mediator activity and facilitating the re-establishment of basal pathway activity.


Influence on Downstream Pathway Regulation

The molecule influences the regulation of processes driven by distinct signaling patterns. By engaging mechanisms that influence feedback regulation within these pathways, Lyseen modifies the kinetics of pathway activation and deactivation and alters the dose-response characteristics of pathway components, resulting in modified physiological endpoints.

Dosage and Administration Information

The administration of Lyseen (Pridinol) follows specific guidelines established for the drug, focusing on the official route, dosage, frequency, and patient-specific conditions.

Official Administration Guidelines

The medicine is primarily available for systemic use via the oral route in tablet form, with injectable solutions available for specific clinical contexts.

Administration Scope Detail
Dosing Schedule (Adults) 1.5 mg to 3 mg pridinol per dose. Tablets are scored for equal division.
Frequency The medicine is taken three times daily (tid).
Intake Conditions Tablets should be swallowed whole with fluid and not chewed.

Contextual and Population-Specific Use

Official instructions specify that administration is independent of meals. However, taking the dose before meals is associated with a faster onset of effect, while patients with low blood pressure are instructed to take the tablets after meals to mitigate the risk of fainting.

The overall duration of use is determined by the prescribing physician, reflecting the use of the medicine as part of a therapeutic regimen.

For specific populations, use must be approached with caution in older adults and in patients with severe renal and/or hepatic insufficiency. This constraint is necessary because higher or longer-lasting blood levels of the drug are expected in these groups. Furthermore, no data are available concerning the use of the medicine in children and adolescents.

Recent Clinical Evidence

Research evidence / Overview of studies for Lyseen (Pridinol)

Evidence for use in Acute Back Pain with Muscular Spasm

Research exploring the use of Lyseen (Pridinol) in conditions involving periods of heightened symptoms, such as acute low back pain associated with muscle tension, is primarily drawn from short-term, randomized controlled trials (RCTs) summarized in meta-analyses. These studies involved adult patients and were used in research exploring how symptoms change over time. The trials examined outcomes related to physical discomfort and daily functioning, such as pain intensity and functional measures like stiffness. The short-term trials described patterns observed in the studies regarding patient-reported outcomes related to perceived discomfort when compared to placebo.

Despite these findings, the outcomes related to systemic or functional imbalance beyond this initial period are not fully established in controlled trials. The most rigorous, placebo-controlled evidence is typically confined to a follow-up duration of approximately three weeks. Additionally, comparative evidence is lacking from large trials that directly study Lyseen against other similar treatments.

Evidence in Other Muscle Pain Syndromes

Research has also explored the role of Lyseen in other conditions marked by functional limitations and muscle stiffness, such as Cervicobrachial Syndrome (pain extending from the neck into the arm). Evidence for these specific conditions often relies on subgroup findings that were extracted from the main analyses of broader muscle pain trials. Findings were mixed; studies report how outcomes related to physical discomfort evolved in the observed populations, and data for certain groups remain insufficient. Prospective research specifically focusing on these individual syndromes is limited.

Evidence in Special Populations and Research Gaps

Studies have also evaluated the medicine as an adjunct (an add-on) therapy alongside physical rehabilitation for older adults with chronic conditions like Lumbar Spondyloarthritis. Evidence quality varies across these studies, and the isolated effect of Lyseen in this elderly population remains uncertain, as the medicine was studied alongside physical interventions.

Scientific reviews indicate several areas where the research evidence is still emerging. Long-term outcomes are not fully established, as follow-up durations were limited in the core studies, and comparative evidence against similar treatments is lacking in many areas.

Frequently Asked Questions (FAQ)

Common questions about Lyseen (FAQ)


Q: What is the storage temperature for this medicine?

Official product information states that Lyseen should be stored at 25 C (77 F). Brief, acceptable temperature excursions are permitted, allowing the medicine to be kept at temperatures between 15 C to 30 C (59 F to 86 F).


Q: Can I take this medicine with food?

Regulatory documents indicate that Lyseen can be taken with or without food. The administration schedule is not dependent on meals.


Q: What are the reasons I should not take this medicine (contraindications)?

Lyseen is contraindicated in patients with known hypersensitivity (an allergic reaction) to the active substance (pregabalin) or to any of the inactive ingredients (excipients) in the formulation. This is the condition listed in regulatory documents that prevents its use.


Q: Can I drink alcohol while taking this medicine?

The official product information states that concurrent use of Lyseen with alcohol or other medicines that slow down the central nervous system (CNS) function may be associated with an increased risk of side effects such as dizziness and somnolence (sleepiness).


Q: Is this medicine safe for women who are pregnant or breastfeeding?

Official information states that Lyseen may cause fetal harm. Due to this potential risk, breastfeeding is not recommended during treatment with this medicine.


Q: Does it make you sleepy?

Yes, dizziness and somnolence (the medical term for sleepiness) are listed in official regulatory documents as very common side effects associated with Lyseen treatment. These are among the most frequently reported adverse reactions.


Q: Can I take this medication if I have a history of heart problems?

The official product information contains a warning regarding the use of Lyseen in patients with underlying cardiovascular conditions. This is based on post-marketing reports of congestive heart failure, which occurred mostly in elderly patients with pre-existing heart problems.


Q: What happens if I stop taking it suddenly?

Regulatory warnings state that abrupt or rapid discontinuation of Lyseen may increase the risk of seizures. Additionally, sudden stopping is associated with withdrawal symptoms, which may include anxiety, insomnia, nausea, headache, and diarrhea.

How should Lyseen be stored and disposed of?

How to Store and Dispose of Lyseen?

Strict storage and disposal protocols must be followed to maintain the quality of Lyseen (Pridinol mesylate) and ensure safety.


Storage Requirements

The medicine must be stored below 25 C and actively protected from light and moisture. It is important that Lyseen is not stored in a refrigerator and not frozen.

For stability, the product must remain in the original container or blister pack and kept tightly closed. Above all, the medicine must be kept out of the sight and reach of children.


Disposal Instructions

Any unused or expired Lyseen must not be thrown away in household rubbish or via wastewater. Disposal must adhere to local regulations for pharmaceutical waste, typically by returning the product to a pharmacist or designated collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lyseen found in:

A-Z Index: